ALBIREO PHARMA INC's ticker is ALBO and the CUSIP is 01345P106. A total of 95 filers reported holding ALBIREO PHARMA INC in Q3 2021. The put-call ratio across all filers is 1.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $237,710 | +3.4% | 11,000 | -7.6% | 0.00% | 0.0% |
| Q3 2022 | $230,000 | -55.4% | 11,900 | -54.2% | 0.00% | 0.0% |
| Q2 2022 | $516,000 | -60.8% | 26,000 | -41.2% | 0.00% | -75.0% |
| Q1 2022 | $1,318,000 | +22.7% | 44,200 | -4.1% | 0.00% | +33.3% |
| Q4 2021 | $1,074,000 | -51.4% | 46,100 | -35.0% | 0.00% | -50.0% |
| Q3 2021 | $2,212,000 | -59.1% | 70,900 | -53.8% | 0.01% | -57.1% |
| Q2 2021 | $5,404,000 | -27.6% | 153,600 | -27.5% | 0.01% | -33.3% |
| Q1 2021 | $7,469,000 | -1.3% | 211,900 | +5.1% | 0.02% | +5.0% |
| Q4 2020 | $7,566,000 | +486.1% | 201,700 | +421.2% | 0.02% | +400.0% |
| Q3 2020 | $1,291,000 | +125.7% | 38,700 | +79.2% | 0.00% | +100.0% |
| Q2 2020 | $572,000 | +105.8% | 21,600 | +27.1% | 0.00% | +100.0% |
| Q1 2020 | $278,000 | +6.1% | 17,000 | +65.0% | 0.00% | 0.0% |
| Q4 2019 | $262,000 | – | 10,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Prosight Management, LP | 514,082 | $11,973,000 | 7.17% |
| Privium Fund Management B.V. | 379,117 | $8,959,000 | 1.78% |
| Birchview Capital, LP | 113,000 | $2,632,000 | 1.70% |
| Sio Capital Management, LLC | 213,913 | $4,982,000 | 1.50% |
| Perceptive Advisors | 4,720,278 | $109,936,000 | 0.85% |
| Chicago Capital, LLC | 849,239 | $19,779,000 | 0.74% |
| APOGEM CAPITAL LLC | 38,601 | $899,000 | 0.59% |
| Samsara BioCapital, LLC | 100,000 | $2,329,000 | 0.45% |
| Artal Group S.A. | 600,000 | $13,974,000 | 0.38% |
| RICE HALL JAMES & ASSOCIATES, LLC | 458,011 | $10,667,000 | 0.38% |